Literature DB >> 154923

Primary soluble plasmic degradation product of human cross-linked fibrin. Isolation and stoichiometry of the (DD)E complex.

S A Olexa, A Z Budzynski.   

Abstract

The formation of the (DD)E complex and fragments DD and E upon proteolysis of human cross-linked fibrin was studied by timed digestions using varying amounts of plasmin. The (DD)E complex was the primary soluble degradation product released form cross-linked fibrin. This complex contained fragments DD and E1. Upon further digestion (DD)E1 complex was cleaved to (DD)E2 complex whereby only the fragment E moiety was affected. However, when fragment E2 was digested to fragment E3, dissociation of the complex occurred. Thus, fragments DD and E3 are the terminal plasmic digestion products of cross-linked fibrin. This pattern was consistent regardless of the plasmin to fibrin ratio; however, the rate of production of the terminal degradation products was directly dependent upon enzyme concentration. Digestion conditions were modified so that either the (DD)E complex or fragment DD was the predominant degradation product, allowing for the purification of these species by one-step gel filtration. The molar ratio of fragment DD to fragment E in the (DD)E complex was investigated by dissociation of the complex and by reassociation of the purified components. The (DD)E complex contains one molecule of fragment DD and one molecule of fragment E.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 154923     DOI: 10.1021/bi00573a009

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Structural basis for sequential cleavage of fibrinopeptides upon fibrin assembly.

Authors:  Igor Pechik; Sergiy Yakovlev; Michael W Mosesson; Gary L Gilliland; Leonid Medved
Journal:  Biochemistry       Date:  2006-03-21       Impact factor: 3.162

2.  Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes.

Authors:  Sergiy Yakovlev; Leonid Medved
Journal:  Thromb Res       Date:  2017-11-21       Impact factor: 3.944

3.  Specific uptake of radioiodinated fragment E1 by venous thrombi in pigs.

Authors:  L C Knight; S A Olexa; L S Malmud; A Z Budzynski
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

4.  Evidence for four different polymerization sites involved in human fibrin formation.

Authors:  S A Olexa; A Z Budzynski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

5.  Breakdown products of fibrin and fibrinogen: molecular mechanisms and clinical implications.

Authors:  P J Gaffney
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

6.  Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.

Authors:  Chunzhang Cao; Daniel A Lawrence; Yang Li; Christine A F Von Arnim; Joachim Herz; Enming J Su; Alexandra Makarova; Bradley T Hyman; Dudley K Strickland; Li Zhang
Journal:  EMBO J       Date:  2006-04-06       Impact factor: 11.598

7.  Determination of fragment D-dimer derivatives in serum reactive with antiserum against human fragment D-dimer.

Authors:  A Matsushima; A Shimizu; Y Takahama; T Tsukada; Y Inada
Journal:  Blut       Date:  1984-08

8.  Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.

Authors:  J I Weitz; B Leslie; J Ginsberg
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.

Authors:  M Matsuda; M Baba; K Morimoto; C Nakamikawa
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

10.  Clinical application of a new latex photometric immunoassay reagent, LPIA-GENESIS D-dimer, and its performance in patient-derived plasma samples.

Authors:  Yutaka Nagahama; Junko Nozaki; George Sakurai; Satoshi Yajima; Noriko Kaneko; Etsuko Yamazaki; Michio Matsuda
Journal:  Int J Lab Hematol       Date:  2020-02-29       Impact factor: 2.877

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.